Tribune Therapeutics AB has performed a private placement directed to Novo Holdings and Inven2 as well as the existing investor HealthCap.
Tribune Therapeutics is a pre-clinical stage biopharmaceutical company which develops a fusion protein to treat patients with fibrotic disease. The private placement is conducted to finance development, clinical trials and commercialisation of the company’s products.
Vinge’s team consisted of Johan Winnerblad, Jesper Lindvall and Annie Fällström (M&A) as well as Stojan Arnerstål and Sofia Bergenstråhle (IP).